Christophe Morisseau

InstitutionUniversity of California Davis
AddressOne Shield Avenue
CA 95616
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Burmistrov V, Morisseau C, Pitushkin D, Karlov D, Fayzullin RR, Butov GM, Hammock BD. Adamantyl thioureas as soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2018 May 23. PMID: 29803731.
      View in: PubMed
    2. Lee KSS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD. Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy. J Med Chem. 2018 May 10; 61(9):4271. PMID: 29701466.
      View in: PubMed
    3. Blöcher R, Wagner KM, Gopireddy RR, Harris TR, Wu H, Barnych B, Hwang SH, Xiang YK, Proschak E, Morisseau C, Hammock BD. Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem. 2018 Apr 26; 61(8):3541-3550. PMID: 29614224.
      View in: PubMed
    4. Hao L, Kearns J, Scott S, Wu D, Kodani SD, Morisseau C, Hammock BD, Sun X, Zhao L, Wang S. Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther. 2018 Jun; 365(3):467-475. PMID: 29567865.
      View in: PubMed
    5. Pecic S, Zeki AA, Xu X, Jin GY, Zhang S, Kodani S, Halim M, Morisseau C, Hammock BD, Deng SX. Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat. 2018 Mar 20. PMID: 29567338.
      View in: PubMed
    6. Yamanashi H, Boeglin WE, Morisseau C, Davis RW, Sulikowski GA, Hammock BD, Brash AR. Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res. 2018 Apr; 59(4):684-695. PMID: 29459481.
      View in: PubMed
    7. Kodani SD, Bhakta S, Hwang SH, Pakhomova S, Newcomer ME, Morisseau C, Hammock BD. Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. Bioorg Med Chem Lett. 2018 Feb 15; 28(4):762-768. PMID: 29366648.
      View in: PubMed
    8. Rand AA, Helmer PO, Inceoglu B, Hammock BD, Morisseau C. LC-MS/MS Analysis of the Epoxides and Diols Derived from the Endocannabinoid Arachidonoyl Ethanolamide. Methods Mol Biol. 2018; 1730:123-133. PMID: 29363071.
      View in: PubMed
    9. Burmistrov V, Morisseau C, Harris TR, Butov G, Hammock BD. Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability. Bioorg Chem. 2018 Feb; 76:510-527. PMID: 29310082.
      View in: PubMed
    10. Deng BQ, Luo Y, Kang X, Li CB, Morisseau C, Yang J, Lee KSS, Huang J, Hu DY, Wu MY, Peng A, Hammock BD, Liu JY. Epoxide metabolites of arachidonate and docosahexaenoate function conversely in acute kidney injury involved in GSK3ß signaling. Proc Natl Acad Sci U S A. 2017 Nov 21; 114(47):12608-12613. PMID: 29109264.
      View in: PubMed
    11. Kodani SD, Barthélemy M, Kamita SG, Hammock B, Morisseau C. Development of amide-based fluorescent probes for selective measurement of carboxylesterase 1 activity in tissue extracts. Anal Biochem. 2017 12 15; 539:81-89. PMID: 29054529.
      View in: PubMed
    12. Hanif A, Edin ML, Zeldin DC, Morisseau C, Falck JR, Ledent C, Tilley SL, Nayeem MA. Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A2A receptor and plasma oxylipins. Prostaglandins Other Lipid Mediat. 2017 Jul; 131:83-95. PMID: 28890385.
      View in: PubMed
    13. Yefidoff-Freedman R, Fan J, Yan L, Zhang Q, Dos Santos GRR, Rana S, Contreras JI, Sahoo R, Wan D, Young J, Dias Teixeira KL, Morisseau C, Halperin J, Hammock B, Natarajan A, Wang P, Chorev M, Aktas BH. Development of 1-((1,4-trans)-4-Aryloxycyclohexyl)-3-arylurea Activators of Heme-Regulated Inhibitor as Selective Activators of the Eukaryotic Initiation Factor 2 Alpha (eIF2a) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response. J Med Chem. 2017 Jul 13; 60(13):5392-5406. PMID: 28590739.
      View in: PubMed
    14. Goswami SK, Rand AA, Wan D, Yang J, Inceoglu B, Thomas M, Morisseau C, Yang GY, Hammock BD. Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers. Life Sci. 2017 Jul 01; 180:114-122. PMID: 28522175.
      View in: PubMed
    15. Li D, Cui Y, Morisseau C, Gee SJ, Bever CS, Liu X, Wu J, Hammock BD, Ying Y. Nanobody Based Immunoassay for Human Soluble Epoxide Hydrolase Detection Using Polymeric Horseradish Peroxidase (PolyHRP) for Signal Enhancement: The Rediscovery of PolyHRP? Anal Chem. 2017 Jun 06; 89(11):6248-6256. PMID: 28460522.
      View in: PubMed
    16. Orcholski ME, Khurshudyan A, Shamskhou EA, Yuan K, Chen IY, Kodani SD, Morisseau C, Hammock BD, Hong EM, Alexandrova L, Alastalo TP, Berry G, Zamanian RT, de Jesus Perez VA. Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2017 08 01; 313(2):L252-L266. PMID: 28473326.
      View in: PubMed
    17. Kitamura S, Morisseau C, Harris TR, Inceoglu B, Hammock BD. Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales. PLoS One. 2017; 12(5):e0176571. PMID: 28472063.
      View in: PubMed
    18. Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, Rock DA, Wang Z. In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s. Drug Metab Dispos. 2017 07; 45(7):712-720. PMID: 28428366.
      View in: PubMed
    19. Rand AA, Barnych B, Morisseau C, Cajka T, Lee KSS, Panigrahy D, Hammock BD. Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. Proc Natl Acad Sci U S A. 2017 04 25; 114(17):4370-4375. PMID: 28396419.
      View in: PubMed
    20. Hvorecny KL, Bahl CD, Kitamura S, Lee KSS, Hammock BD, Morisseau C, Madden DR. Active-Site Flexibility and Substrate Specificity in a Bacterial Virulence Factor: Crystallographic Snapshots of an Epoxide Hydrolase. Structure. 2017 05 02; 25(5):697-707.e4. PMID: 28392259.
      View in: PubMed
    21. Wagner K, Gilda J, Yang J, Wan D, Morisseau C, Gomes AV, Hammock BD. Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice. Behav Brain Res. 2017 05 30; 326:69-76. PMID: 28259677.
      View in: PubMed
    22. Hanif A, Edin ML, Zeldin DC, Morisseau C, Falck JR, Nayeem MA. Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and ?-Hydroxylases. PLoS One. 2017; 12(1):e0169584. PMID: 28056085.
      View in: PubMed
    23. Flitter BA, Hvorecny KL, Ono E, Eddens T, Yang J, Kwak DH, Bahl CD, Hampton TH, Morisseau C, Hammock BD, Liu X, Lee JS, Kolls JK, Levy BD, Madden DR, Bomberger JM. Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators. Proc Natl Acad Sci U S A. 2017 01 03; 114(1):136-141. PMID: 27980032.
      View in: PubMed
    24. Hwang SH, Wagner K, Xu J, Yang J, Li X, Cao Z, Morisseau C, Lee KS, Hammock BD. Chemical synthesis and biological evaluation of ?-hydroxy polyunsaturated fatty acids. Bioorg Med Chem Lett. 2017 02 01; 27(3):620-625. PMID: 28025003.
      View in: PubMed
    25. Lee KS, Henriksen NM, Ng CJ, Yang J, Jia W, Morisseau C, Andaya A, Gilson MK, Hammock BD. Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase. Arch Biochem Biophys. 2017 Jan 01; 613:1-11. PMID: 27983948.
      View in: PubMed
    26. Liu JY, Morisseau C, Huang H, Hammock BD. Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use. J Ethnopharmacol. 2016 Dec 24; 194:475-482. PMID: 27702689.
      View in: PubMed
    27. Kodani SD, Overby HB, Morisseau C, Chen J, Zhao L, Hammock BD. Parabens inhibit fatty acid amide hydrolase: A potential role in paraben-enhanced 3T3-L1 adipocyte differentiation. Toxicol Lett. 2016 Nov 16; 262:92-99. PMID: 27659731.
      View in: PubMed
    28. Hanif A, Edin ML, Zeldin DC, Morisseau C, Nayeem MA. Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPAR?. PLoS One. 2016; 11(9):e0162147. PMID: 27583776; PMCID: PMC5008628.
    29. Hanif A, Edin ML, Zeldin DC, Morisseau C, Nayeem MA. Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: role of oxylipins and PPAR?. Am J Physiol Regul Integr Comp Physiol. 2016 10 01; 311(4):R676-R688. PMID: 27488890.
      View in: PubMed
    30. Xu J, Morisseau C, Yang J, Lee KSS, Kamita SG, Hammock BD. Ingestion of the epoxide hydrolase inhibitor AUDA modulates immune responses of the mosquito, Culex quinquefasciatus during blood feeding. Insect Biochem Mol Biol. 2016 09; 76:62-69. PMID: 27369469; PMCID: PMC5010450 [Available on 09/01/17].
    31. Wu X, Yang J, Morisseau C, Robertson LW, Hammock B, Lehmler HJ. 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) Decreases Hepatic and Systemic Ratios of Epoxide to Diol Metabolites of Unsaturated Fatty Acids in Male Rats. Toxicol Sci. 2016 08; 152(2):309-22. PMID: 27208083.
      View in: PubMed
    32. Mouchlis VD, Morisseau C, Hammock BD, Li S, McCammon JA, Dennis EA. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2. Bioorg Med Chem. 2016 10 15; 24(20):4801-4811. PMID: 27320659.
      View in: PubMed
    33. Kitamura S, Hvorecny KL, Niu J, Hammock BD, Madden DR, Morisseau C. Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa. J Med Chem. 2016 05 26; 59(10):4790-9. PMID: 27120257; PMCID: PMC4957648 [Available on 05/26/17].
    34. Goswami SK, Wan D, Yang J, Trindade da Silva CA, Morisseau C, Kodani SD, Yang GY, Inceoglu B, Hammock BD. Anti-Ulcer Efficacy of Soluble Epoxide Hydrolase Inhibitor TPPU on Diclofenac-Induced Intestinal Ulcers. J Pharmacol Exp Ther. 2016 06; 357(3):529-36. PMID: 26989141; PMCID: PMC4885505.
    35. Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner KM, Zhang JC, Yang C, Yao W, Dong C, Han M, Hammock BD, Hashimoto K. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci U S A. 2016 Mar 29; 113(13):E1944-52. PMID: 26976569; PMCID: PMC4822604.
    36. McLellan GJ, Aktas Z, Hennes-Beean E, Kolb AW, Larsen IV, Schmitz EJ, Clausius HR, Yang J, Hwang SH, Morisseau C, Inceoglu B, Hammock BD, Brandt CR. Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit. J Ocul Biol. 2016 Jan; 4(1). PMID: 28066796.
      View in: PubMed
    37. Rossotti MA, Pirez M, Gonzalez-Techera A, Cui Y, Bever CS, Lee KS, Morisseau C, Leizagoyen C, Gee S, Hammock BD, González-Sapienza G. Method for Sorting and Pairwise Selection of Nanobodies for the Development of Highly Sensitive Sandwich Immunoassays. Anal Chem. 2015 Dec 01; 87(23):11907-14. PMID: 26544909; PMCID: PMC4666776 [Available on 12/01/16].
    38. Goswami SK, Inceoglu B, Yang J, Wan D, Kodani SD, da Silva CA, Morisseau C, Hammock BD. Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE2 induced pain model. Toxicol Appl Pharmacol. 2015 Dec 15; 289(3):419-27. PMID: 26522832; PMCID: PMC4666679 [Available on 12/15/16].
    39. Burmistrov V, Morisseau C, Danilov D, Harris TR, Dalinger I, Vatsadze I, Shkineva T, Butov GM, Hammock BD. 1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2015 Dec 01; 25(23):5514-9. PMID: 26520661; PMCID: PMC4654407 [Available on 12/01/16].
    40. Liu JY, Tsai HJ, Morisseau C, Lango J, Hwang SH, Watanabe T, Kim IH, Hammock BD. In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors. Biochem Pharmacol. 2015 Dec 15; 98(4):718-31. PMID: 26494425; PMCID: PMC4656071 [Available on 12/15/16].
    41. Deng LM, Li XP, Xu DY, Morisseau C, Chiamvimonvat N, Hammock BD. Aerobic exercise-based rehabilitation affects the activities of progenitor endothelial cells through EETs pathway. Med Hypotheses. 2015 Dec; 85(6):1037-8. PMID: 26454561.
      View in: PubMed
    42. Cui Y, Li D, Morisseau C, Dong JX, Yang J, Wan D, Rossotti MA, Gee SJ, González-Sapienza GG, Hammock BD. Heavy chain single-domain antibodies to detect native human soluble epoxide hydrolase. Anal Bioanal Chem. 2015 Sep; 407(24):7275-83. PMID: 26229025; PMCID: PMC4573264.
    43. Bahl CD, Hvorecny KL, Bomberger JM, Stanton BA, Hammock BD, Morisseau C, Madden DR. Inhibiting an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa Protects CFTR. Angew Chem Int Ed Engl. 2015 Aug 17; 54(34):9881-5. PMID: 26136396; PMCID: PMC4556431.
    44. Ostermann AI, Herbers J, Willenberg I, Chen R, Hwang SH, Greite R, Morisseau C, Gueler F, Hammock BD, Schebb NH. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern. Prostaglandins Other Lipid Mediat. 2015 Sep; 121(Pt A):131-7. PMID: 26117215; PMCID: PMC4688279.
    45. Roche C, Guerrot D, Harouki N, Duflot T, Besnier M, Rémy-Jouet I, Renet S, Dumesnil A, Lejeune A, Morisseau C, Richard V, Bellien J. Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice. Prostaglandins Other Lipid Mediat. 2015 Jul; 120:148-54. PMID: 26022136; PMCID: PMC4575616.
    46. Sasso O, Wagner K, Morisseau C, Inceoglu B, Hammock BD, Piomelli D. Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. Pharmacol Res. 2015 Jul; 97:7-15. PMID: 25882247; PMCID: PMC4464910.
    47. Roche C, Besnier M, Cassel R, Harouki N, Coquerel D, Guerrot D, Nicol L, Loizon E, Remy-Jouet I, Morisseau C, Mulder P, Ouvrard-Pascaud A, Madec AM, Richard V, Bellien J. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice. Am J Physiol Heart Circ Physiol. 2015 May 01; 308(9):H1020-9. PMID: 25724490; PMCID: PMC4551118.
    48. Nollmann FI, Heinrich AK, Brachmann AO, Morisseau C, Mukherjee K, Casanova-Torres ÁM, Strobl F, Kleinhans D, Kinski S, Schultz K, Beeton ML, Kaiser M, Chu YY, Phan Ke L, Thanwisai A, Bozhüyük KA, Chantratita N, Götz F, Waterfield NR, Vilcinskas A, Stelzer EH, Goodrich-Blair H, Hammock BD, Bode HB. A Photorhabdus natural product inhibits insect juvenile hormone epoxide hydrolase. Chembiochem. 2015 Mar 23; 16(5):766-71. PMID: 25711603; PMCID: PMC4486325.
    49. Shen L, Peng H, Peng R, Fan Q, Zhao S, Xu D, Morisseau C, Chiamvimonvat N, Hammock BD. Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis. Atherosclerosis. 2015 Apr; 239(2):557-65. PMID: 25733327.
      View in: PubMed
    50. Xu J, Morisseau C, Yang J, Mamatha DM, Hammock BD. Epoxide hydrolase activities and epoxy fatty acids in the mosquito Culex quinquefasciatus. Insect Biochem Mol Biol. 2015 Apr; 59:41-9. PMID: 25686802; PMCID: PMC4387068.
    51. Kitamura S, Morisseau C, Inceoglu B, Kamita SG, De Nicola GR, Nyegue M, Hammock BD. Potent natural soluble epoxide hydrolase inhibitors from Pentadiplandra brazzeana baillon: synthesis, quantification, and measurement of biological activities in vitro and in vivo. PLoS One. 2015; 10(2):e0117438. PMID: 25659109; PMCID: PMC4319826.
    52. Bettaieb A, Morisseau C, Hammock B, Haj F. Soluble epoxide hydrolase deficiency ameliorates acute pancreatitis in mice. Free Radic Biol Med. 2014 Oct; 75 Suppl 1:S32. PMID: 26461340.
      View in: PubMed
    53. Shihadih DS, Harris TR, Yang J, Merzlikin O, Lee KS, Hammock BD, Morisseau C. Identification of potent inhibitors of the chicken soluble epoxide hydrolase. Bioorg Med Chem Lett. 2015 Jan 15; 25(2):276-9. PMID: 25479771; PMCID: PMC4277729.
    54. Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD. Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol. 2015 Jan; 75(1):161-71. PMID: 25413440; PMCID: PMC4400119.
    55. Bettaieb A, Chahed S, Tabet G, Yang J, Morisseau C, Griffey S, Hammock BD, Haj FG. Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in mice. PLoS One. 2014; 9(11):e113019. PMID: 25402489; PMCID: PMC4234494.
    56. Terry CM, Carlson ML, He Y, Ulu A, Morisseau C, Blumenthal DK, Hammock BD, Cheung AK. Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model. J Vasc Res. 2014; 51(4):269-82. PMID: 25196102; PMCID: PMC4235611.
    57. Xu J, Morisseau C, Hammock BD. Expression and characterization of an epoxide hydrolase from Anopheles gambiae with high activity on epoxy fatty acids. Insect Biochem Mol Biol. 2014 Nov; 54:42-52. PMID: 25173592; PMCID: PMC4252830.
    58. Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem. 2014 Aug 28; 57(16):7016-30. PMID: 25079952.
      View in: PubMed
    59. Sarnpitak P, Mujumdar P, Morisseau C, Hwang SH, Hammock B, Iurchenko V, Zozulya S, Gavalas A, Geronikaki A, Ivanenkov Y, Krasavin M. Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core. Eur J Med Chem. 2014 Sep 12; 84:160-72. PMID: 25016374.
      View in: PubMed
    60. Charles RL, Rudyk O, Prysyazhna O, Kamynina A, Yang J, Morisseau C, Hammock BD, Freeman BA, Eaton P. Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase. Proc Natl Acad Sci U S A. 2014 Jun 03; 111(22):8167-72. PMID: 24843165; PMCID: PMC4050620.
    61. Morisseau C, Wecksler AT, Deng C, Dong H, Yang J, Lee KS, Kodani SD, Hammock BD. Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation. J Lipid Res. 2014 Jun; 55(6):1131-8. PMID: 24771868; PMCID: PMC4031944.
    62. Burmistrov V, Morisseau C, Lee KS, Shihadih DS, Harris TR, Butov GM, Hammock BD. Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2014 May 01; 24(9):2193-7. PMID: 24685540; PMCID: PMC4019751.
    63. Kálai T, Altman R, Maezawa I, Balog M, Morisseau C, Petrlova J, Hammock BD, Jin LW, Trudell JR, Voss JC, Hideg K. Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors. Eur J Med Chem. 2014 Apr 22; 77:343-50. PMID: 24657571; PMCID: PMC4065883.
    64. Inceoglu B, Zolkowska D, Yoo HJ, Wagner KM, Yang J, Hackett E, Hwang SH, Lee KS, Rogawski MA, Morisseau C, Hammock BD. Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures. PLoS One. 2013; 8(12):e80922. PMID: 24349022; PMCID: PMC3862847.
    65. Chen T, Takrouri K, Hee-Hwang S, Rana S, Yefidoff-Freedman R, Halperin J, Natarajan A, Morisseau C, Hammock B, Chorev M, Aktas BH. Explorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinase. J Med Chem. 2013 Dec 12; 56(23):9457-70. PMID: 24261904; PMCID: PMC3938169.
    66. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013 Sep; 62(3):285-97. PMID: 23676336; PMCID: PMC3773051.
    67. Kamita SG, Oshita GH, Wang P, Morisseau C, Hammock BD, Nandety RS, Falk BW. Characterization of Hovi-mEH1, a microsomal epoxide hydrolase from the glassy-winged sharpshooter Homalodisca vitripennis. Arch Insect Biochem Physiol. 2013 Aug; 83(4):171-9. PMID: 23704009; PMCID: PMC3846607.
    68. Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Bioorg Med Chem Lett. 2013 Jul 01; 23(13):3732-7. PMID: 23726028; PMCID: PMC3744640.
    69. Morisseau C, Pakhomova S, Hwang SH, Newcomer ME, Hammock BD. Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides. Bioorg Med Chem Lett. 2013 Jul 01; 23(13):3818-21. PMID: 23684894; PMCID: PMC3703951.
    70. Bettaieb A, Nagata N, AbouBechara D, Chahed S, Morisseau C, Hammock BD, Haj FG. Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue. J Biol Chem. 2013 May 17; 288(20):14189-99. PMID: 23576437; PMCID: PMC3656275.
    71. Guedes AG, Morisseau C, Sole A, Soares JH, Ulu A, Dong H, Hammock BD. Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis. Vet Anaesth Analg. 2013 Jul; 40(4):440-8. PMID: 23463912; PMCID: PMC3956586.
    72. North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE. Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem. 2013 May 01; 21(9):2587-99. PMID: 23498915; PMCID: PMC3780361.
    73. Liu JY, Lin YP, Qiu H, Morisseau C, Rose TE, Hwang SH, Chiamvimonvat N, Hammock BD. Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. Eur J Pharm Sci. 2013 Mar 12; 48(4-5):619-27. PMID: 23291046; PMCID: PMC3596469.
    74. de Medina P, Paillasse MR, Segala G, Voisin M, Mhamdi L, Dalenc F, Lacroix-Triki M, Filleron T, Pont F, Saati TA, Morisseau C, Hammock BD, Silvente-Poirot S, Poirot M. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nat Commun. 2013; 4:1840. PMID: 23673625; PMCID: PMC3674249.
    75. Wagner K, Inceoglu B, Dong H, Yang J, Hwang SH, Jones P, Morisseau C, Hammock BD. Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models. Eur J Pharmacol. 2013 Jan 30; 700(1-3):93-101. PMID: 23276668; PMCID: PMC3578047.
    76. Kamita SG, Yamamoto K, Dadala MM, Pha K, Morisseau C, Escaich A, Hammock BD. Cloning and characterization of a microsomal epoxide hydrolase from Heliothis virescens. Insect Biochem Mol Biol. 2013 Mar; 43(3):219-28. PMID: 23276675; PMCID: PMC3577957.
    77. Chen L, Fan C, Zhang Y, Bakri M, Dong H, Morisseau C, Maddipati KR, Luo P, Wang CY, Hammock BD, Wang MH. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:42-8. PMID: 23247129; PMCID: PMC4052893.
    78. Lee KS, Morisseau C, Yang J, Wang P, Hwang SH, Hammock BD. Förster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase. Anal Biochem. 2013 Mar 15; 434(2):259-68. PMID: 23219719; PMCID: PMC3632402.
    79. Morisseau C, Sahdeo S, Cortopassi G, Hammock BD. Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries. Anal Biochem. 2013 Mar 01; 434(1):105-11. PMID: 23219563; PMCID: PMC3557602.
    80. Pecic S, Pakhomova S, Newcomer ME, Morisseau C, Hammock BD, Zhu Z, Rinderspacher A, Deng SX. Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2013 Jan 15; 23(2):417-21. PMID: 23237835; PMCID: PMC3541548.
    81. Nayeem MA, Pradhan I, Mustafa SJ, Morisseau C, Falck JR, Zeldin DC. Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPAR?. Am J Physiol Regul Integr Comp Physiol. 2013 Jan 01; 304(1):R23-32. PMID: 23152114; PMCID: PMC3543649.
    82. Falck D, Schebb NH, Prihatiningtyas S, Zhang J, Heus F, Morisseau C, Kool J, Hammock BD, Niessen WM. Development of On-line Liquid Chromatography-Biochemical Detection for Soluble Epoxide Hydrolase Inhibitors in Mixtures. Chromatographia. 2013 Jan 01; 76(1-2):13-21. PMID: 23526703.
      View in: PubMed
    83. Tamang DL, Pirzai W, Priebe GP, Traficante DC, Pier GB, Falck JR, Morisseau C, Hammock BD, McCormick BA, Gronert K, Hurley BP. Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers. J Immunol. 2012 Nov 15; 189(10):4960-9. PMID: 23045615; PMCID: PMC3490410.
    84. Morisseau C, Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol. 2013; 53:37-58. PMID: 23020295; PMCID: PMC3578707.
    85. Kim IH, Nishi K, Kasagami T, Morisseau C, Liu JY, Tsai HJ, Hammock BD. Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase. Bioorg Med Chem Lett. 2012 Sep 15; 22(18):5889-92. PMID: 22901393; PMCID: PMC3432147.
    86. Decker M, Adamska M, Cronin A, Di Giallonardo F, Burgener J, Marowsky A, Falck JR, Morisseau C, Hammock BD, Gruzdev A, Zeldin DC, Arand M. EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides. J Lipid Res. 2012 Oct; 53(10):2038-45. PMID: 22798687; PMCID: PMC3435537.
    87. Inceoglu B, Wagner KM, Yang J, Bettaieb A, Schebb NH, Hwang SH, Morisseau C, Haj FG, Hammock BD. Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11390-5. PMID: 22733772; PMCID: PMC3396532.
    88. Morisseau C. Role of epoxide hydrolases in lipid metabolism. Biochimie. 2013 Jan; 95(1):91-5. PMID: 22722082; PMCID: PMC3495083.
    89. Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM. Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor. Am J Physiol Cell Physiol. 2012 Aug 01; 303(3):C278-90. PMID: 22621785; PMCID: PMC3423029.
    90. Xu DY, Davis BB, Wang ZH, Zhao SP, Wasti B, Liu ZL, Li N, Morisseau C, Chiamvimonvat N, Hammock BD. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPAR? to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. Int J Cardiol. 2013 Aug 20; 167(4):1298-304. PMID: 22525341; PMCID: PMC3821736.
    91. Scherman MS, North EJ, Jones V, Hess TN, Grzegorzewicz AE, Kasagami T, Kim IH, Merzlikin O, Lenaerts AJ, Lee RE, Jackson M, Morisseau C, McNeil MR. Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. Bioorg Med Chem. 2012 May 15; 20(10):3255-62. PMID: 22522007; PMCID: PMC3345085.
    92. Huang SX, Cao B, Morisseau C, Jin Y, Hammock BD, Long YQ. Structure-based optimization of the piperazino-containing 1,3-disubstituted ureas affording sub-nanomolar inhibitors of soluble epoxide hydrolase. Medchemcomm. 2012 Mar 01; (3):379-384. PMID: 25225606.
      View in: PubMed
    93. Morisseau C, Schebb NH, Dong H, Ulu A, Aronov PA, Hammock BD. Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids. Biochem Biophys Res Commun. 2012 Mar 23; 419(4):796-800. PMID: 22387545; PMCID: PMC3313618.
    94. Duan H, Takagi A, Kayano H, Koyama I, Morisseau C, Hammock BD, Akatsuka T. Monoclonal antibodies reveal multiple forms of expression of human microsomal epoxide hydrolase. Toxicol Appl Pharmacol. 2012 Apr 01; 260(1):27-34. PMID: 22306621; PMCID: PMC3319120.
    95. Duan H, Yoshimura K, Kobayashi N, Sugiyama K, Sawada J, Saito Y, Morisseau C, Hammock BD, Akatsuka T. Development of monoclonal antibodies to human microsomal epoxide hydrolase and analysis of "preneoplastic antigen"-like molecules. Toxicol Appl Pharmacol. 2012 Apr 01; 260(1):17-26. PMID: 22310175; PMCID: PMC3319115.
    96. Villalon Landeros R, Morisseau C, Yoo HJ, Fu SH, Hammock BD, Trainor BC. Corncob bedding alters the effects of estrogens on aggressive behavior and reduces estrogen receptor-a expression in the brain. Endocrinology. 2012 Feb; 153(2):949-53. PMID: 22186416; PMCID: PMC3275391.
    97. Hou HH, Hammock BD, Su KH, Morisseau C, Kou YR, Imaoka S, Oguro A, Shyue SK, Zhao JF, Lee TS. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc Res. 2012 Jan 01; 93(1):120-9. PMID: 22072631; PMCID: PMC3243038.
    98. Pecic S, Deng SX, Morisseau C, Hammock BD, Landry DW. Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2012 Jan 01; 22(1):601-5. PMID: 22079754; PMCID: PMC3337727.
    99. Iyer A, Kauter K, Alam MA, Hwang SH, Morisseau C, Hammock BD, Brown L. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res. 2012; 2012:758614. PMID: 22007192; PMCID: PMC3191770.
    100. Brown JR, North EJ, Hurdle JG, Morisseau C, Scarborough JS, Sun D, Korduláková J, Scherman MS, Jones V, Grzegorzewicz A, Crew RM, Jackson M, McNeil MR, Lee RE. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg Med Chem. 2011 Sep 15; 19(18):5585-95. PMID: 21840723.
      View in: PubMed
    101. Liu JY, Qiu H, Morisseau C, Hwang SH, Tsai HJ, Ulu A, Chiamvimonvat N, Hammock BD. Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model. Toxicol Appl Pharmacol. 2011 Sep 01; 255(2):200-6. PMID: 21741984; PMCID: PMC3156297.
    102. Schebb NH, Huby M, Morisseau C, Hwang SH, Hammock BD. Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors. Anal Bioanal Chem. 2011 May; 400(5):1359-66. PMID: 21479549; PMCID: PMC3081056.
    103. Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Wecksler AT, Hammock BD. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J Med Chem. 2011 Apr 28; 54(8):3037-50. PMID: 21434686; PMCID: PMC3281519.
    104. Barhoumi R, Mouneimne Y, Ramos E, Morisseau C, Hammock BD, Safe S, Parrish AR, Burghardt RC. Multiphoton spectral analysis of benzo[a]pyrene uptake and metabolism in a rat liver cell line. Toxicol Appl Pharmacol. 2011 May 15; 253(1):45-56. PMID: 21420996; PMCID: PMC3081912.
    105. Inceoglu B, Wagner K, Schebb NH, Morisseau C, Jinks SL, Ulu A, Hegedus C, Rose T, Brosnan R, Hammock BD. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A. 2011 Mar 22; 108(12):5093-7. PMID: 21383170; PMCID: PMC3064364.
    106. Schebb NH, Inceoglu B, Ahn KC, Morisseau C, Gee SJ, Hammock BD. Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects. Environ Sci Technol. 2011 Apr 01; 45(7):3109-15. PMID: 21381656; PMCID: PMC3470465.
    107. Morisseau C, Bernay M, Escaich A, Sanborn JR, Lango J, Hammock BD. Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies. Anal Biochem. 2011 Jul 01; 414(1):154-62. PMID: 21371418; PMCID: PMC3090455.
    108. Koeners MP, Wesseling S, Ulu A, Sepúlveda RL, Morisseau C, Braam B, Hammock BD, Joles JA. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats. Am J Physiol Endocrinol Metab. 2011 Apr; 300(4):E691-8. PMID: 21266668; PMCID: PMC3074945.
    109. Charles RL, Burgoyne JR, Mayr M, Weldon SM, Hubner N, Dong H, Morisseau C, Hammock BD, Landar A, Eaton P. Redox regulation of soluble epoxide hydrolase by 15-deoxy-delta-prostaglandin J2 controls coronary hypoxic vasodilation. Circ Res. 2011 Feb 04; 108(3):324-34. PMID: 21164107.
      View in: PubMed
    110. Huang SX, Li HY, Liu JY, Morisseau C, Hammock BD, Long YQ. Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem. 2010 Dec 09; 53(23):8376-86. PMID: 21070033.
      View in: PubMed
    111. Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, Hammock BD. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem. 2010 Oct 14; 53(19):7067-75. PMID: 20812725; PMCID: PMC3285450.
    112. Jung O, Jansen F, Mieth A, Barbosa-Sicard E, Pliquett RU, Babelova A, Morisseau C, Hwang SH, Tsai C, Hammock BD, Schaefer L, Geisslinger G, Amann K, Brandes RP. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One. 2010 Aug 04; 5(8):e11979. PMID: 20694143; PMCID: PMC2915917.
    113. Morisseau C, Inceoglu B, Schmelzer K, Tsai HJ, Jinks SL, Hegedus CM, Hammock BD. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res. 2010 Dec; 51(12):3481-90. PMID: 20664072; PMCID: PMC2975720.
    114. Kamita SG, Wogulis MD, Law CS, Morisseau C, Tanaka H, Huang H, Wilson DK, Hammock BD. Function of phenylalanine 259 and threonine 314 within the substrate binding pocket of the juvenile hormone esterase of Manduca sexta. Biochemistry. 2010 May 04; 49(17):3733-42. PMID: 20307057; PMCID: PMC3570046.
    115. Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C, Wang CY, Inscho EW, Hammock BD, Wang MH. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 2010 Aug; 334(2):430-8. PMID: 20439437; PMCID: PMC2913776.
    116. Nayeem MA, Zeldin DC, Boegehold MA, Morisseau C, Marowsky A, Ponnoth DS, Roush KP, Falck JR. Modulation by salt intake of the vascular response mediated through adenosine A(2A) receptor: role of CYP epoxygenase and soluble epoxide hydrolase. Am J Physiol Regul Integr Comp Physiol. 2010 Jul; 299(1):R325-33. PMID: 20427718.
      View in: PubMed
    117. Tsai HJ, Hwang SH, Morisseau C, Yang J, Jones PD, Kasagami T, Kim IH, Hammock BD. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci. 2010 Jun 14; 40(3):222-38. PMID: 20359531; PMCID: PMC3285443.
    118. Revermann M, Schloss M, Barbosa-Sicard E, Mieth A, Liebner S, Morisseau C, Geisslinger G, Schermuly RT, Fleming I, Hammock BD, Brandes RP. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2010 May; 30(5):909-14. PMID: 20224052; PMCID: PMC2919323.
    119. Townsley MI, Morisseau C, Hammock B, King JA. Impact of epoxyeicosatrienoic acids in lung ischemia-reperfusion injury. Microcirculation. 2010 Feb; 17(2):137-46. PMID: 20163540; PMCID: PMC2923642.
    120. Bahl CD, Morisseau C, Bomberger JM, Stanton BA, Hammock BD, O'Toole GA, Madden DR. Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J Bacteriol. 2010 Apr; 192(7):1785-95. PMID: 20118260; PMCID: PMC2838060.
    121. Matveeva EG, Morisseau C, Goodrow MH, Mullin C, Hammock BD. Tryptophan fluorescence quenching by enzyme inhibitors as a tool for enzyme active site structure investigation: epoxide hydrolase. Curr Pharm Biotechnol. 2009 Sep; 10(6):589-99. PMID: 19619123; PMCID: PMC2861369.
    122. Falck JR, Kodela R, Manne R, Atcha KR, Puli N, Dubasi N, Manthati VL, Capdevila JH, Yi XY, Goldman DH, Morisseau C, Hammock BD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem. 2009 Aug 27; 52(16):5069-75. PMID: 19653681; PMCID: PMC2888647.
    123. Barbosa-Sicard E, Frömel T, Keserü B, Brandes RP, Morisseau C, Hammock BD, Braun T, Krüger M, Fleming I. Inhibition of the soluble epoxide hydrolase by tyrosine nitration. J Biol Chem. 2009 Oct 09; 284(41):28156-63. PMID: 19704161; PMCID: PMC2788866.
    124. Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther. 2009 Aug; 8(8):2193-203. PMID: 19671760; PMCID: PMC2728155.
    125. Morisseau C, Merzlikin O, Lin A, He G, Feng W, Padilla I, Denison MS, Pessah IN, Hammock BD. Toxicology in the fast lane: application of high-throughput bioassays to detect modulation of key enzymes and receptors. Environ Health Perspect. 2009 Dec; 117(12):1867-72. PMID: 20049205; PMCID: PMC2799460.
    126. De Taeye BM, Morisseau C, Coyle J, Covington JW, Luria A, Yang J, Murphy SB, Friedman DB, Hammock BB, Vaughan DE. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring). 2010 Mar; 18(3):489-98. PMID: 19644452; PMCID: PMC2864128.
    127. Luria A, Morisseau C, Tsai HJ, Yang J, Inceoglu B, De Taeye B, Watkins SM, Wiest MM, German JB, Hammock BD. Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase. Am J Physiol Endocrinol Metab. 2009 Aug; 297(2):E375-83. PMID: 19458064; PMCID: PMC2724109.
    128. Huang H, Tanaka H, Hammock BD, Morisseau C. Novel and highly sensitive fluorescent assay for leucine aminopeptidases. Anal Biochem. 2009 Aug 01; 391(1):11-6. PMID: 19433052; PMCID: PMC2748848.
    129. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, Fleming I, Hammock BD, Brandes RP. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens. 2009 Feb; 27(2):322-31. PMID: 19226702; PMCID: PMC2863009.
    130. Kasagami T, Kim IH, Tsai HJ, Nishi K, Hammock BD, Morisseau C. Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15; 19(6):1784-9. PMID: 19216074; PMCID: PMC2900318.
    131. Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C, Hammock BD. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol. 2009 Jan; 156(2):284-96. PMID: 19154430; PMCID: PMC2697843.
    132. Rawal S, Morisseau C, Hammock BD, Shivachar AC. Differential subcellular distribution and colocalization of the microsomal and soluble epoxide hydrolases in cultured neonatal rat brain cortical astrocytes. J Neurosci Res. 2009 Jan; 87(1):218-27. PMID: 18711743; PMCID: PMC3592782.
    133. Inceoglu B, Jinks SL, Ulu A, Hegedus CM, Georgi K, Schmelzer KR, Wagner K, Jones PD, Morisseau C, Hammock BD. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A. 2008 Dec 02; 105(48):18901-6. PMID: 19028872; PMCID: PMC2596245.
    134. Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Fiehn O, Hammock BD, Weiss RH. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol. 2008 Oct; 52(4):314-23. PMID: 18791465; PMCID: PMC2637359.
    135. Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther. 2008 Dec; 327(3):707-15. PMID: 18815352; PMCID: PMC2761654.
    136. Xie Y, Liu Y, Gong G, Smith DH, Yan F, Rinderspacher A, Feng Y, Zhu Z, Li X, Deng SX, Branden L, Vidovic D, Chung C, Schürer S, Morisseau C, Hammock BD, Landry DW. Discovery of potent non-urea inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2009 Apr 15; 19(8):2354-9. PMID: 19303288; PMCID: PMC2738751.
    137. Biswal BK, Morisseau C, Garen G, Cherney MM, Garen C, Niu C, Hammock BD, James MN. The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. J Mol Biol. 2008 Sep 12; 381(4):897-912. PMID: 18585390; PMCID: PMC2866126.
    138. Morisseau C, Hammock BD. Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical. Pest Manag Sci. 2008 Jun; 64(6):594-609. PMID: 18383502.
      View in: PubMed
    139. Jiang H, Zhu AG, Mamczur M, Morisseau C, Hammock BD, Falck JR, McGiff JC. Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells. J Pharmacol Exp Ther. 2008 Jul; 326(1):330-7. PMID: 18445784; PMCID: PMC2732189.
    140. Parrish AR, Chen G, Burghardt RC, Watanabe T, Morisseau C, Hammock BD. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol. 2009 Jun; 25(3):217-25. PMID: 18386137; PMCID: PMC3033346.
    141. Morisseau C, Newman JW, Wheelock CE, Hill Iii T, Morin D, Buckpitt AR, Hammock BD. Development of metabolically stable inhibitors of Mammalian microsomal epoxide hydrolase. Chem Res Toxicol. 2008 Apr; 21(4):951-7. PMID: 18363382.
      View in: PubMed
    142. Tanaka H, Kamita SG, Wolf NM, Harris TR, Wu Z, Morisseau C, Hammock BD. Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2. Biochim Biophys Acta. 2008 Jan; 1779(1):17-27. PMID: 18078836; PMCID: PMC2699939.
    143. Kim IH, Tsai HJ, Nishi K, Kasagami T, Morisseau C, Hammock BD. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem. 2007 Oct 18; 50(21):5217-26. PMID: 17894481; PMCID: PMC2543935.
    144. Fleming I, Rueben A, Popp R, Fisslthaler B, Schrodt S, Sander A, Haendeler J, Falck JR, Morisseau C, Hammock BD, Busse R. Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol. 2007 Dec; 27(12):2612-8. PMID: 17872452.
      View in: PubMed
    145. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 09; 50(16):3825-40. PMID: 17616115; PMCID: PMC2596069.
    146. Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD, Wang MH. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol. 2007 Jul; 293(1):F342-9. PMID: 17442729.
      View in: PubMed
    147. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab. 2007 Dec; 27(12):1931-40. PMID: 17440491; PMCID: PMC2664093.
    148. Akatsuka T, Kobayashi N, Ishikawa T, Saito T, Shindo M, Yamauchi M, Kurokohchi K, Miyazawa H, Duan H, Matsunaga T, Komoda T, Morisseau C, Hammock BD. Autoantibody response to microsomal epoxide hydrolase in hepatitis C and A. J Autoimmun. 2007 Feb; 28(1):7-18. PMID: 17296285; PMCID: PMC1892246.
    149. Chiappe C, Leandri E, Hammock BD, Morisseau C. Effect of ionic liquids on epoxide hydrolase-catalyzed synthesis of chiral 1,2-diols. Green Chem. 2007; 2007(9):162-168. PMID: 18160974.
      View in: PubMed
    150. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys. 2007; 47(1):87-98. PMID: 17406062; PMCID: PMC1892223.
    151. Morisseau C, Hammock BD. Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protoc Toxicol. 2007; Chapter 4:Unit 4.23. PMID: 23045145.
      View in: PubMed
    152. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, Hammock BD. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem. 2007 Feb 02; 282(5):2891-8. PMID: 17135253; PMCID: PMC2040337.
    153. Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD. Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett. 2006 Oct 15; 16(20):5439-44. PMID: 16908134; PMCID: PMC1892215.
    154. Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, Hammock BD. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem. 2007 Jan 01; 15(1):312-23. PMID: 17046265; PMCID: PMC2040326.
    155. Hwang SH, Morisseau C, Do Z, Hammock BD. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15; 16(22):5773-7. PMID: 16949285; PMCID: PMC1904340.
    156. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol. 2006 Nov; 26(11):2462-8. PMID: 16917105; PMCID: PMC1904341.
    157. Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 01; 16(19):5212-6. PMID: 16870439; PMCID: PMC1904344.
    158. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 2007 Jan; 82(1-4):42-9. PMID: 17164131; PMCID: PMC1904338.
    159. Li HY, Jin Y, Morisseau C, Hammock BD, Long YQ. The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolase. Bioorg Med Chem. 2006 Oct 01; 14(19):6586-92. PMID: 16784862; PMCID: PMC2040075.
    160. Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther. 2006 Sep; 318(3):1307-14. PMID: 16772540.
      View in: PubMed
    161. Wolf NM, Morisseau C, Jones PD, Hock B, Hammock BD. Development of a high-throughput screen for soluble epoxide hydrolase inhibition. Anal Biochem. 2006 Aug 01; 355(1):71-80. PMID: 16729954; PMCID: PMC1964503.
    162. Watanabe T, Schulz D, Morisseau C, Hammock BD. High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal Chim Acta. 2006 Feb 10; 559(1):37-44. PMID: 16636700.
      View in: PubMed
    163. Nishi K, Huang H, Kamita SG, Kim IH, Morisseau C, Hammock BD. Characterization of pyrethroid hydrolysis by the human liver carboxylesterases hCE-1 and hCE-2. Arch Biochem Biophys. 2006 Jan 01; 445(1):115-23. PMID: 16359636; PMCID: PMC1444892.
    164. Gomez GA, Morisseau C, Hammock BD, Christianson DW. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci. 2006 Jan; 15(1):58-64. PMID: 16322563; PMCID: PMC1762130.
    165. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A. 2005 Nov 15; 102(46):16747-52. PMID: 16267130; PMCID: PMC1276614.
    166. Davis BB, Morisseau C, Newman JW, Pedersen TL, Hammock BD, Weiss RH. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther. 2006 Feb; 316(2):815-21. PMID: 16221742.
      View in: PubMed
    167. Tran KL, Aronov PA, Tanaka H, Newman JW, Hammock BD, Morisseau C. Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. Biochemistry. 2005 Sep 13; 44(36):12179-87. PMID: 16142916; PMCID: PMC1473036.
    168. Jones PD, Wolf NM, Morisseau C, Whetstone P, Hock B, Hammock BD. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem. 2005 Aug 01; 343(1):66-75. PMID: 15963942; PMCID: PMC1447601.
    169. Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19; 48(10):3621-9. PMID: 15887969; PMCID: PMC1450255.
    170. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res. 2005 Jan; 44(1):1-51. PMID: 15748653.
      View in: PubMed
    171. Sellers KW, Sun C, Diez-Freire C, Waki H, Morisseau C, Falck JR, Hammock BD, Paton JF, Raizada MK. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J. 2005 Apr; 19(6):626-8. PMID: 15659536.
      View in: PubMed
    172. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol. 2005; 45:311-33. PMID: 15822179.
      View in: PubMed
    173. Hennebold JD, Mah K, Perez W, Vance JE, Stouffer RL, Morisseau C, Hammock BD, Adashi EY. Identification and characterization of an ovary-selective isoform of epoxide hydrolase. Biol Reprod. 2005 Apr; 72(4):968-75. PMID: 15601917.
      View in: PubMed
    174. Stok JE, Goloshchapov A, Song C, Wheelock CE, Derbel MB, Morisseau C, Hammock BD. Investigation of the role of a second conserved serine in carboxylesterases via site-directed mutagenesis. Arch Biochem Biophys. 2004 Oct 15; 430(2):247-55. PMID: 15369824.
      View in: PubMed
    175. Stok JE, Huang H, Jones PD, Wheelock CE, Morisseau C, Hammock BD. Identification, expression, and purification of a pyrethroid-hydrolyzing carboxylesterase from mouse liver microsomes. J Biol Chem. 2004 Jul 09; 279(28):29863-9. PMID: 15123619.
      View in: PubMed
    176. Gomez GA, Morisseau C, Hammock BD, Christianson DW. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry. 2004 Apr 27; 43(16):4716-23. PMID: 15096040.
      View in: PubMed
    177. Kim IH, Morisseau C, Watanabe T, Hammock BD. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem. 2004 Apr 08; 47(8):2110-22. PMID: 15056008.
      View in: PubMed
    178. Koivunen ME, Morisseau C, Horwath WR, Hammock BD. Isolation of a strain of Agrobacterium tumefaciens (Rhizobium radiobacter) utilizing methylene urea (ureaformaldehyde) as nitrogen source. Can J Microbiol. 2004 Mar; 50(3):167-74. PMID: 15105883.
      View in: PubMed
    179. DuTeaux SB, Newman JW, Morisseau C, Fairbairn EA, Jelks K, Hammock BD, Miller MG. Epoxide hydrolases in the rat epididymis: possible roles in xenobiotic and endogenous fatty acid metabolism. Toxicol Sci. 2004 Apr; 78(2):187-95. PMID: 14737000.
      View in: PubMed
    180. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol. 2004 Apr; 286(4):F720-6. PMID: 14665429.
      View in: PubMed
    181. Watanabe T, Morisseau C, Newman JW, Hammock BD. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea. Drug Metab Dispos. 2003 Jul; 31(7):846-53. PMID: 12814960.
      View in: PubMed
    182. Wheelock CE, Wheelock AM, Zhang R, Stok JE, Morisseau C, Le Valley SE, Green CE, Hammock BD. Evaluation of alpha-cyanoesters as fluorescent substrates for examining interindividual variation in general and pyrethroid-selective esterases in human liver microsomes. Anal Biochem. 2003 Apr 15; 315(2):208-22. PMID: 12689831.
      View in: PubMed
    183. McElroy NR, Jurs PC, Morisseau C, Hammock BD. QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J Med Chem. 2003 Mar 13; 46(6):1066-80. PMID: 12620084.
      View in: PubMed
    184. Newman JW, Morisseau C, Harris TR, Hammock BD. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1558-63. PMID: 12574510; PMCID: PMC149871.
    185. Severson TF, Goodrow MH, Morisseau C, Dowdy DL, Hammock BD. Urea and amide-based inhibitors of the juvenile hormone epoxide hydrolase of the tobacco hornworm (Manduca sexta: Sphingidae). Insect Biochem Mol Biol. 2002 Dec; 32(12):1741-56. PMID: 12429126.
      View in: PubMed
    186. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau C, Doris PA. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension. 2002 Oct; 40(4):485-90. PMID: 12364351.
      View in: PubMed
    187. Fang X, Weintraub NL, Oltman CL, Stoll LL, Kaduce TL, Harmon S, Dellsperger KC, Morisseau C, Hammock BD, Spector AA. Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide. Am J Physiol Heart Circ Physiol. 2002 Dec; 283(6):H2306-14. PMID: 12388281.
      View in: PubMed
    188. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol. 2002 May 01; 63(9):1599-608. PMID: 12007563.
      View in: PubMed
    189. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2002 Feb 19; 99(4):2222-7. PMID: 11842228; PMCID: PMC122346.
    190. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002 Feb; 39(2 Pt 2):690-4. PMID: 11882632.
      View in: PubMed
    Christophe's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Related Authors
    People who share related concepts with this person.